| 0.04 | 0.13% |
| SLXP Salix Pharmaceuticals Ltd. | Trade It Now | | NASDAQ |
| |
Market Cap 1.601B Book Value 7.093 EBITDA -27.2M Year Low 7.40 Year High 32.03 PEG Ratio 14.42 EPS -0.884 P/B Ratio 4.32 Short Ratio 3.30 Index Membership S&P 600 SmallCap S&P  Sector Healthcare Industry Drug Related Products Open 30.74 High 30.91 Low 30.27 Last Close 30.64 Volume 916.2 K Target Price 41.33 Current EPS -0.884 This Year EPS 0.05 Next Year EPS 1.48 This Year PE 612.80 Next Year PE 20.70 Salix Pharmaceuticals Ltd.1700 Perimeter Park Drive Morrisville,
NC 27560-8404 United States - Map
Phone: 919-862-1000
Fax: 919-862-1095
Web Site: VisitType: Stock | | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-03-17 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-03-17 |  | |
|
Community Discussions | | | 0.00 | 0.00% |
| MDNU Medical Nutrition USA Inc. | Trade It Now | | NCM |
| |
Market Cap 28.5M Book Value 0.954 EBITDA 724K Year Low 0.95 Year High 2.97 EPS 0.009 P/E 231.12 P/B Ratio 2.18 Short Ratio 0.80 Sector Healthcare Full Time Employees 36 Industry Drug Related Products Last Close 2.0801 Target Price 8.25 Current EPS 0.009 Current PE 231.12 Medical Nutrition USA, Inc.10 West Forest Avenue Englewood,
NJ 07631 United States - Map
Phone: 201-569-1188
Fax: 201-569-3224
Web Site: VisitType: Stock | | Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. |
Company Summary more  Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. The company’s customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes,... Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. The company’s customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey. Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. The company’s customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes,... Top Stories| |
Market Report -- In Play (MDNU)
MSN Money - Feb 17, 2010
Medical Nutrition USA sees Q4 revs of $4.4 mln vs. $3.7 mln a year ago; EPS of $0.01-0.02 vs. ($0.01) a year ago Branded product sales for the quarter increased 21 percent to $4.1 million from $3 ...
2010-02-17 |  | |
| | | 2010-02-17 |  | |
| | | 2010-02-17 |  | |
| | | 2010-02-10 |  | |
|
Community Discussions |